Evidence map›Paper›PMID 39719556›Full record

ArticleBMC biotechnology2024

Aripiprazole-loaded niosome/chitosan-gold nanoparticles for breast cancer chemo-photo therapy.

Sajjad Alimohammadvand, Masoumeh Kaveh Zenjanab, Parvin Samadi Pakchin, Elaheh Dalir Abdolahinia, Jaleh Barar, Yadollah Omidi, Mohammad M Pourseif, Marziyeh Fathi, Jalal Shayegh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sajjad AlimohammadvandResearch Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Masoumeh Kaveh ZenjanabResearch Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Parvin Samadi PakchinResearch Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Elaheh Dalir AbdolahiniaResearch Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Jaleh BararDepartment of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, USA.
Yadollah OmidiDepartment of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, USA.
Mohammad M PourseifResearch Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Marziyeh FathiResearch Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran. fathi.marziyeh@yahoo.com.
Jalal ShayeghDepartment of Microbiology, Faculty of Veterinary and Agriculture, Islamic Azad University, Shabestar Branch, Shabestar, Iran. jalalshayegh@gmail.com.

Funding

Tabriz University of Medical Sciences 68893
6 · The paper itself

Abstract

introductionBreast cancer, a formidable global health challenge for women, necessitates innovative therapeutic strategies with enhanced efficacy and minimal side effects. Aripiprazole (ARI), a widely used schizophrenia medication, exhibits promising potential in the treatment of breast cancer. As cancer therapy evolves towards a combination approach, multimodal nano-based delivery systems, such as ARI-loaded niosomes (NIOs) combined with Chitosan-Au nanoparticles for chemo-photothermal therapy, show promise over traditional chemotherapy alone by enhancing targeted efficacy and minimizing side effects.

methodsIn this study, a niosomal formulation was designed, incorporating ARI and chitosan-coated AuNPs (i.e. NIOs/AuNPs-CS/ARI), to study the synergistic effect of photothermal/chemotherapy in breast cancer cells.

resultsThe nanosystems were characterized using UV-Vis spectroscopy and Fourier-transform infrared spectroscopy (FT-IR), confirming the successful synthesis steps. The hydrodynamic diameter of NIOs/AuNPs-CS was determined to be 44.62 nm with a zeta potential of -0.836. Also, Transmission Electron Microscopy (TEM) and Field-Emission Scanning Electron Microscopical (FE-SEM) analysis were performed to assess the size and morphology of NPs. The loading efficiency of ARI in NIOs and NIOs/AuNPs-CS was 75% and 88%, respectively. Furthermore, the release rate of the drug from NIOs/AuNPs-CS is higher than blank NIOs at two pH values (5.8 and 7.4). The cellular uptake of AuNPs-CS-encapsulated NIOs was considerably higher than that of blank NIOs. The Annexin V/PI staining assay showed that the apoptosis/necrosis rate was high in NIOs/AuNPs-CS/ARI (46%) and NIOs/ARI (36%) in 48 h. The results of MTT assessments demonstrated higher cytotoxicity by ARI-loaded NPs. The viability of MCF-7 cells treated with NIOs/AuNPs-CS/ARI was reduced from 60% and 50% to 40% and 20%, respectively, after 24 and 48 h upon laser irradiation.

conclusionThe results of this experiment demonstrated the remarkable effectiveness of NIOs/AuNPs-CS/ARI in cancer treatment, owing to their unique properties, including the PTT capability and pH sensitivity.

Indexed as

AripiprazoleBreast NeoplasmsChitosanGoldLiposomesMetal NanoparticlesAntineoplastic AgentsCell Line, TumorCell SurvivalFemaleHumansMCF-7 CellsAntineoplastic AgentsAripiprazoleChitosanGoldLiposomesAripiprazoleBreast cancerChitosanCombination therapyGold nanoparticlesNiosomesPhotothermal therapy

Identifiers

PMID39719556
PMCPMC11668004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.